

# Imugene Ltd

02:46 15 Jul 2019

## Imugene to acquire exclusive licence for potentially transformational oncolytic virus technology

Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) is to acquire the worldwide exclusive licence to oncolytic virus technology known as CF33.

Development and commercialisation of CF33, a chimeric vaccinia poxvirus, will be funded through Imugene's existing cash reserves and will include ex-Viralytics members as part of its project development team.

Imugene chief executive officer Leslie Chong said the company was delighted to licence such a promising next-generation oncolytic virus (OV) in a competitive marketplace, where big pharma companies are actively seeking OV technologies.

Oncolytic viruses are designed to both selectively kill tumours cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.

The viruses have the potential to transform oncology by directly causing tumour cell death and also by delivering a potent payload in a targeted fashion that activates the immune system.

### READ: Imugene reveals new clinical data for HER-Vaxx vaccine showing cancer-fighting response

Chong continued: "CF33 comes with robust intellectual property and long patent life, compelling pre-clinical efficacy and safety and is anticipated to enter a phase-one clinical trial in 2020.

"The opportunity to separately engage with members of the ex-Viralytics team through Vaxinia was cogent for immune.

"[It] bring to Imugene senior executives with direct involvement in two of the largest OV transaction in biotech history being Amgen's acquisition of Biovex for US\$950 million and Merck's acquisition of Viralytics for A\$502 million."

### READ: Imugene presents new HER-Vaxx cancer vaccine results

The drug was initially developed at Los Angeles-based City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases.

In consideration for the exclusive licence, City of Hope will receive from Imugene licence fees comprising an upfront, annual maintenance fee creditable against future royalty payments.


The company will also pay performance-based consideration linked to achieving certain milestones and commercial outcomes, as well as net sales-based royalty payments and sub-licencing fees.

### READ: Imugene well-funded to progress clinical milestones

**Price:** 0.034

**Market Cap:** \$150.48 m

#### 1 Year Share Price Graph



#### Share Information

**Code:** IMU

**Listing:** ASX

**52 week High Low**  
0.063 0.013

**Sector:** Pharma & Biotech

**Website:** www.imugene.com

#### Company Synopsis:

Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

As part of the transaction, Imugene entered into a binding agreement to acquire 100% of Vaxinia, of which Imugene executive chairman Paul Hopper is major shareholder.

The transaction includes an up-front cash payment of A\$462,500 and the issue of ordinary fully paid Imugene shares valued at A\$1.619 million, based on the seven-day volume weighted average price.

The decision to acquire Vaxinia was made by Imugene's independent directors, with Hopper recused from the process given he is a beneficiary of the transaction.

**READ: Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx**

Shareholders of Vaxinia include, along with Hopper, City of Hope chair of surgery Professor Yuman Fong, the inventor of CF33, and an ex-Viralytics executive.

They will be eligible for further payments in equity on the achievement of performance-related milestones.

These milestones will be further detailed in the company's notice to meeting and will include granting of investigational new drug status by the Federal Drug Administration (FDA), dosing the first patient in a phase-one clinical trial and the phase-one clinical trial demonstrating safety.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

**No investment advice**

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).